Lumark

Lutetium (177Lu) Chloride is a radiopharmaceutical used in targeted therapy. This intravenous medication is manufactured by Idb Holland B.V. and is sourced from the EU.

Lutetium (177Lu) Chloride is primarily used in targeted radiotherapy. This radiopharmaceutical is designed to deliver radiation directly to specific cells, which may help in managing certain conditions. It is often explored for its potential in targeted treatment approaches.

Lutetium (177Lu) Chloride works by emitting radiation that can affect the targeted cells. Common effects may include localized responses, and patients are typically monitored for any reactions during and after administration.

Handling Lutetium (177Lu) Chloride requires careful consideration due to its radioactive properties. It should be administered by trained healthcare professionals in a controlled environment. Patients should follow all safety guidelines provided by their healthcare provider.

Lutetium (177Lu) Chloride may interact with other medications or treatments. It is important to inform healthcare providers about all current medications and treatments before administration. Specific interactions should be discussed with a healthcare professional.